In silico bioavailability for BCS class II efavirenz tablets using biorelevant dissolution media for IVIVR and simulation of formulation changes.
Thalita Martins da SilvaThiago da Silva HonórioMarcelo Henrique da Cunha ChavesMarcelo Dutra DuqueLucio Mendes CabralBeatriz Ferreira de Carvalho PatricioHelvécio Vinícius Antunes RochaPublished in: Drug development and industrial pharmacy (2021)
The present work provides valuable information about efavirenz solubility and kinetics in the gastrointestinal tract, allowing an IVIVR to support future formulation changes. This understanding is essential for rational science-driven formulation development. At least, this study also showed the validity and applicability of in vitro and in silico tools in the regulatory scenario helping on drug development.